There is much interest in finding a therapeutic window for commonly used neuroleptics so that dosage can be individualized and side effects minimized. The authors review specific requirements of good study design and survey the literature that has investigated the relationship between therapeutic response and plasma concentrations of neuroleptics. The evidence from a number of fixed-dose haloperidol studies suggests, but does not yet prove, the existence of a therapeutic window for this compound.
Get full access to this article
View all access options for this article.
References
1.
SimpsonGMPiEHSramekJJ. Neuroleptics and antipsychotics. In: DukesMNG, ed. Meyler's side effects of drugs. New York: Elsevier Science Publishers, 1984: 95–108.
2.
DonlonPTHopkinJTupinJP. Overview: Efficacy and safety of the rapid neuroleptization method with injectable haloperidol. J Clin Psychopharmacol1985; 136: 273–8.
3.
TupinJP. Focal neuroleptization: An approach to optimal dosing for initial and continuing therapy. J Clin Psychopharmacol1985; 5 (suppl): 155–215.
4.
McCreadieKGMacdonaldIM. High dosage haloperidol in chronic schizophrenia. Br J Psychiatry1977; 131: 310–6.
5.
KimDYHollisterLE. Thiothixene in the intensive treatment of drug-refractory chronic schizophrenics: Doses and plasma concentrations. Scientific exhibit, 34th American Psychiatric Association Institute on Hospital and Community Psychiatry, October, 1982, Louisville, KY.
6.
DonlonPTHopkinJTTupinJPWicksJJWahbaMMeadowA. Haloperidol for acute schizophrenic patients: An evaluation of three oral regimens. Arch Gen Psychiatry1980; 37: 691–5.
PotkinSHahnRSramekJ. Plasma neuroleptic concentrations: In search of a therapeutic window. Clin Neuropharmacol1986; 9: 256–8.
9.
PotkinSGShenYPardesH. Haloperidol concentrations elevated in Chinese patients. Psychiatry Res1984; 12: 167–72.
10.
SramekJJSaylesMASimpsonGM. Neuroleptic dosage for Asians: A failure to replicate. Am J Psychiatry1986; 143: 535–6.
11.
PantuckEJPantuckCBAndersonKEConneyAHKappasA. Cigarette smoking and chlorpromazine disposition and actions. Clin Pharmacol Ther1982; 31: 533–8.
12.
SramekJHerreraJRoyS. An analysis of steady-state chlorpromazine plasma levels in the clinical setting. J Clin Psychopharmacol1987; 7: 117–8.
13.
CurryS. Commentary: The strategy and value of neuroleptic drug monitoring. J Clin Psychopharmacol1985; 5: 263–71.
14.
SimpsonGMKashinathY. Blood levels of neuroleptics: State of the art. J Clin Psychiatry1985; 46 (sec 2): 22–8.
15.
SnyderSH. Dopamine receptors, neuroleptics and schizophrenia. Am J Psychiatry1981; 138: 460–4.
16.
MayPRAVan PuttenT. Plasma levels of chlorpromazine in schizophrenia. Arch Gen Psychiatry1978; 38: 202–7.
17.
Van PuttenTMarderSR. Variable dose studies provide misleading therapeutic windows. J Clin Psychopharmacol1986; 6: 55–6.
18.
GarverDLBeasleyCSautterTNormanAChopiaY. Early antipsychotic response with neuroleptics and dopamine psychosis. Poster presentation, 26th Annual Meeting, American College of Neuropsychopharmacology, December 7–11, 1987, San Juan, Puerto Rico.
19.
Van PuttenTMarderSRMayPRA. Plasma level of haloperidol and clinical response. Psychopharmacol Bull1985; 21: 69–72.
20.
SramekJHerreraJCostaJ. Persistence of neuroleptic levels after drug discontinuation. J Clin Psychopharmacol1987; 7: 436–7.
21.
McCreadieRGMackieMWilesDHJorgensenAHansenVMenziesC. Within individual variation in steady-state plasma levels of different neuroleptics and prolactin. Br J Psychiatry1984; 144: 625–9.
AndreasenNC. Positive vs. negative schizophrenia: A critical evaluation. Schizophrenia Bull1985; 11: 380–9.
24.
CrowT. The two-syndrome concept: Origins and current status. Schizophrenia Bull1985; 11: 471–86.
25.
CurrySHMarshallJHLDavisJMJanowskyDS. Chlorpromazine plasma levels and effects. Arch Gen Psychiatry1970; 22: 289–96.
26.
TornatoreFLLeeDSramekJJ. Psychotic exacerbation with haloperidol. Drug Intell Clin Pharm1981; 15: 209–13.
27.
ExteinIPottashALCGoldMS. Therapeutic window for haloperidol plasma levels in acute schizophrenic patients. Lancet1983; 1: 1048–9.
28.
SimpsonGM. CNS effects of neuroleptic agents. Psychiatr Ann1975; 5: 347–51.
29.
Rivera-CalimlinLCastanedaLLasagnaL. Effects of mode of management on plasma chlorpromazine in psychiatric patients. Clin Pharmacol Ther1973; 14: 978–86.
30.
Rivera-CalimlinLNasrallahHStraussJLasagnaL. Clinical response and plasma levels: Effect of dose, dosage schedules and drug interactions on plasma chlorpromazine levels. Am J Psychiatry1976; 133: 646–52.
31.
Rivera-CalimlinLGiftTNasrallahHA. Correlation between plasma levels of chlorpromazine and clinical response of psychiatric patients. Psychopharmacol Commun1978; 2: 215–22.
32.
SakalisGCurrySHMouldGP. Physiologic and clinical effects of chlorpromazine and their relationship to plasma level. Clin Pharmacol Ther1972; 13: 931–46.
33.
Van PuttenTMayPRAJendenDJ. Plasma levels of chlorpromazine and clinical response. Psychopharmacol Bull1981; 17: 113–5.
34.
MayPRAVan PuttenTJendenDJYaleCDixonWJ. Chlorpromazine levels and the outcome of treatment of schizophrenic patients. Arch Gen Psychiatry1981; 38: 202–7.
35.
Wode-HelgodtBBorgSFyroBSedvallG. Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatr Scand1978; 58: 149–73.
36.
MackayAVHealeyAFBakeJ. The relationship of plasma CPZ to 7-OH and sulphoxide metabolites in a large population of chronic schizophrenics. Br J Clin Pharmacol1974; 1: 425–30.
37.
SakuraiY. Prediction of response to CPZ treatment in schizophrenics. Psychopharmacologia1975; 44: 195–203.
38.
PhillipsonOTMcKloumJMBakerJHealsyAF. Correlation of plasma CPZ and its metabolites and clinical ratings in patients with acute relapse of schizophrenic and paranoid psychosis. Br J Psychiatry1977; 131: 172–84.
39.
DyskenMWJavaidJLChangSS. Flupenazine pharmacokinetics and therapeutic response. Psychopharmacology1981; 73: 205–10.
40.
MayroidisMKanterDRHirschowitzJ. Therapeutic blood levels of fluphenazine: Plasma or RBC determinations?Psychopharmacol Bull1984; 20: 168–70.
41.
JaniakPGJavaidJISharmaRComatyJEPetersonJDavisJM. Trifluoperazine plasma levels and clinical response. Poster presentation, 26th Annual Meeting, American College of Neuropsychopharmacology, December 7–11, 1987, San Juan, Puerto Rico.
42.
NiedzwieckiDMMailmanRBCubedduLX. Greater potency of mesoridazine and sulforidazine compared with the parent compound, thioridazine, on striatal dopamine autoreceptors. J Clin Exp Ther1984; 228: 636–9.
43.
MayPRATokarJRDavisJM. Plasma thioridazine and therapeutic response in schizophrenia. In: GottschalkLA, ed. Pharmacokinetics of psychoactive drugs: Further studies. New York: Spectrum, 1979.
44.
CohenBMLipinskeJFPopeHG. Neuroleptic blood levels and therapeutic effect. Psychopharmacology1980; 70: 191–3.
45.
BerglinRMjorndalTOrelandL. Plasma levels and clinical effects of thioridazine. J Clin Pharmacol1975; 15: 178–86.
46.
ForsmanAOhmanR. Applied pharmacokinetics of haloperidol in man. Curr Ther Res1977; 21: 396–411.
47.
ReiflerBVWardNDavisCMFreidelRO. Thiothixene plasma levels and clinical response in acute schizophrenia. J Clin Psychiatry1981; 42: 207–11.
48.
Van PuttenTMayPRAMarderSR. Plasma levels of thiothixene by radioreceptor assay: Clinical usefulness. Psychopharmacology1983; 79: 40–4.
KimBYHollisterLE. Drug-refractory chronic schizophrenics: Doses and plasma concentrations of thiothixene. J Clin Psychopharmacol1984; 4: 32–5.
51.
YesavageJABeckerJWernerPDMillsMJHolmanCACohnR. Serum level monitoring of thiothixene in schizophrenia: Acute single-dose levels at fixed doses. Am J Psychiatry1982; 139: 174–8.
52.
GarverDLDekirmenjianHDavisJM. Neuroleptic drug levels and therapeutic response: Preliminary observations with red blood cell bound butaperazine. Am J Psychiatry1977; 134: 304–7.
53.
CasperRGarverDLDekirmenjianH. Phenothiazine levels in plasma and red blood cells. Arch Gen Psychiatry1980; 37: 301–5.
54.
KorpiERCostakosDTWyattRJ. Interconversions of haloperidol and reduced haloperidol in guinea pig and rat liver microsomes. Biochem Pharmacol1985; 34: 2923–7.
55.
VolavkaJCooperTB. Review of haloperidol blood level and clinical response: Looking through the window. J Clin Psychopharmacol1987; 7: 25–30.
56.
MidhaKKHawesEMHubbardJWKorchinskiEDMcKayG. Interconversion between haloperidol and reduced haloperidol in humans. J Clin Psychopharmacol1987; 7: 362–4.
57.
DavisCM EreshefskylHarringtonCA. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients. J Clin Psychopharmacol1984; 4: 138–42.
58.
KorpiERKoGNPhelpsBHWyattRJ. Possible interference by the reduced haloperidol metabolite with the radioimmunoassay and radioreceptor assay of blood haloperidol. J Clin Psychopharmacol1984; 4: 332–5.
59.
BartkoGHerczegIBekesyM. Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement. J Clin Psychiatry1987; 48: 363–5.
60.
SmithRCVroulisGShvartsburdA. RBC and plasma levels of haloperidol and clinical response in schizophrenia. Am J Psychiatry1982; 139: 1054–6.
61.
MavroidisMLKanterDRHirschowitzJ. Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology1981; 81: 354–6.
62.
GarverDLHirschowitzJGlicksteenGAKanterDRMavroidisML. Haloperidol plasma and red blood cell levels and clinical antipsychotic response. J Clin Psychopharmacol1984; 4: 133–7.
63.
SmithRCBaumgartnerRMisraCH. Haloperidol: Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: Chemical v. radioreceptor plasma level assays. Arch Gen Psychiatry1984; 41: 1044–9.
64.
PotkinSGShenYZhouDI. Does a therapeutic window for plasma haloperidol exist? Preliminary Chinese data. Psychopharmacol Bull1985; 21: 59–61.
65.
DavisJEricksenSEHuntS. Haloperidol plasma levels and clinical response: Basic concepts and clinical data. Psychopharmacol Bull1985; 21: 48–51.
66.
RimonRAverbuchHRozickP. Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients. Psychopharmacology1981; 73: 197–9.
67.
CohenBMBaldessariniRJ. Haloperidol and clinical response. Am J Psychiatry1981; 138: 1513–4.
68.
LinkowskiPHubainPVon FrenckellR. Haloperidol plasma levels and clinical response in paranoid schizophrenics. Eur Arch Psychiatr Neurol Sci1984; 234: 231–6.
69.
BleekerJACDingemansPMFrohnDE. Plasma level and effect of low-dose haloperidol in acute psychosis. Psychopharmacol Bull1984; 20: 317–9.
70.
ItohHYagiGTateyamaM. Monitoring of haloperidol serum levels and its clinical significance. Prog Neuropsychopharmacol Biol Psychiatr1984; 8: 51–62.
71.
WistedtBJohanideszGOmerhodzicM. Plasma haloperidol levels and clinical response in acute schizophrenia. Nord Psychiatr Tidsskr1984; 1: 9–13.
72.
BigelowLBKirchDGBraunT. Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenia. Psychopharmacol Bull1985; 21: 66–8.
73.
SmithRC. Plasma haloperidol levels and clinical response. Arch Gen Psychiatry1987; 44: 1110–2.
74.
ShostakMPerelJMStillerRLWymanWCurranS. Plasma haloperidol and clinical response: A role for reduced haloperidol in antipsychotic activity. J Clin Psychopharmacol1987; 7: 394–400.
75.
HollisterLEKimBY. Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients. Am J Psychiatry1982; 139: 1466–8.
76.
MillerDDHerseyLADuffyJPAbernethyDRGreenblattDJ. Serum haloperidol concentrations and clinical response in acute psychosis. J Clin Psychopharmacol1984; 4: 305–10.
77.
TuneLECreeseIDepauloJRSlavneyPRCoyleJTSnyderSH. Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia. Am J Psychiatry1980; 137: 187–90.
78.
ExteinIAugusthyKAGoldMS. Plasma haloperidol levels and clinical response in acute schizophrenia. Psychopharmacol Bull1982; 18: 156–8.
79.
MagliozziJRHollisterLEArnoldKVEarleGM. Relationship of serum haloperidol levels to clinical response in schizophrenic patients. Am J Psychiatry1981; 138: 365–7.
McEvoyJPStillerRLFarrR. Plasma haloperidol levels drawn at neuroleptic threshold doses: A pilot study. J Clin Psychopharmacol1986; 6: 133–8.
82.
ConlonPTHopkinJTTupinJPWicksJJWahbaMMeadowA. Haloperidol for acute schizophrenia patients: An evaluation of three oral regimens. Arch Gen Psychiatry1980; 37: 195–9.
83.
NeborskyRJanowskyDMunsonEDepryD. Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol. Arch Gen Psychiatry1981; 38: 195–9.
